Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Correction: Effect of alirocum...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Correction: Effect of alirocumab on cataracts in patients with acute coronary syndromes

Correction: Effect of alirocumab on cataracts in patients with acute coronary syndromes

Bibliographic Details
Main Authors: Gaspard Suc, Gregory G. Schwartz, Shaun G. Goodman, J. Wouter Jukema, Garen Manvelian, Yann Poulouin, Robert Pordy, Michel Scemama, Michael Szarek, Ph.Gabriel Steg, ODYSSEY OUTCOMES Investigators
Format: Article
Language:English
Published: BMC 2023-07-01
Series:BMC Ophthalmology
Online Access:https://doi.org/10.1186/s12886-023-03065-2
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://doi.org/10.1186/s12886-023-03065-2

Similar Items

  • Effect of alirocumab on cataracts in patients with acute coronary syndromes
    by: Gaspard Suc, et al.
    Published: (2023-06-01)
  • Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial
    by: Shaun G. Goodman, et al.
    Published: (2023-09-01)
  • Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials
    by: Kusha A. Mohammadi, et al.
    Published: (2023-08-01)
  • Alirocumab and chest pain after acute coronary syndrome: An analysis of ODYSSEY OUTCOMES
    by: Gregory P. Geba, et al.
    Published: (2024-12-01)
  • Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE
    by: Maciej Banach, et al.
    Published: (2021-10-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs